Search Result "multiple-modified LDL"
Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients' Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity
Journal: Current Pharmaceutical Design
Volume: 23 Issue: 6 Year: 2017 Page: 932-936
Author(s): Nikita G. Nikifirov,Emile R. Zakiev,Natalia V. Elizova,Vasily N. Sukhorukov,Alexander N. Orekhov
Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?
Journal: Current Medicinal Chemistry
Volume: 26 Issue: 9 Year: 2019 Page: 1665-1679
Author(s): Andrea Rivas-Urbina,Anna Rull,Jordi Ordóñez-Llanos,José Luis Sánchez-Quesada
Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Journal: Current Drug Delivery
Volume: 18 Issue: 7 Year: 2021 Page: 1027-1040
Author(s): Md Masum Rizwee,Minhal Abidi,Safia Habib,Abdul Rouf Mir,Asif Ali,Moin Uddin
New Lipid-lowering Agents Acting on LDL Receptors
Journal: Current Topics in Medicinal Chemistry
Volume: 5 Issue: 3 Year: 2005 Page: 233-242
Author(s): Hubert Scharnagl, Winfried Marz
Role of Ox-LDL and LOX-1 in Atherogenesis
Journal: Current Medicinal Chemistry
Volume: 26 Issue: 9 Year: 2019 Page: 1693-1700
Author(s): Ajoe John Kattoor,Sri Harsha Kanuri,Jawahar L. Mehta
LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options
Journal: Current Pharmaceutical Design
Volume: 20 Issue: 4 Year: 2014 Page: 6249-6255
Author(s): Antonio Garcia-Rios, Dragana Nikolic, Pablo Perez-Martinez, Jose Lopez-Miranda, Manfredi Rizzo, Ron C. Hoogeveen
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Journal: Current Vascular Pharmacology
Volume: 9 Issue: 5 Year: 2011 Page: 533-571
Author(s): Dimitri P. Mikhailidis, Moses Elisaf, Manfredi Rizzo, Kaspar Berneis, Bruce Griffin, Alberto Zambon, Vasilios Athyros, Jacqueline de Graaf, Winfried Marz, Klaus G. Parhofer, Giovam Battista Rini, Giatgen A. Spinas, Gerald H. Tomkin, Alexandros D. Tselepis, Anthony S. Wierzbicki, Karl Winkler, Matilda Florentin, Evangelos Liberopoulos
Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease
Journal: Current Pharmaceutical Design
Volume: 13 Issue: 1 Year: 2007 Page: 1021-1030
Author(s): Jan Nilsson, Gunilla Nordin Fredrikson, Alexandru Schiopu, Prediman K. Shah, Bo Jansson, Roland Carlsson
Possible Non-Classic Intracellular and Molecular Mechanisms of LDL Cholesterol Action Contributing to the Development and Progression of Atherosclerosis
Journal: Current Vascular Pharmacology
Volume: 2 Issue: 4 Year: 2004 Page: 363-370
Author(s): Ioanna Gouni-Berthold, Agapios Sachinidis
Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Journal: Current Pharmaceutical Design
Volume: 19 Issue: 2 Year: 2013 Page: 3858-3868
Author(s): Manfredi Rizzo, Marcin Barylski, Ali A. Rizvi, Giuseppe Montalto, Dimitri P. Mikhailidis, Maciej Banach